{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:42:46Z","timestamp":1790181766701,"version":"4.1.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background and Objective:<\/jats:bold>\n                    Tacrolimus, a calcineurin inhibitor widely used as a potent immunosuppressant to prevent graft rejection, exhibits nonlinear kinetics in patients with kidney transplantation and nephrotic syndrome. However, whether nonlinear drug metabolism occurs in adult patients undergoing liver transplantation remains unclear, as do the main underlying mechanisms. Therefore, here we aimed to further confirm the characteristics of nonlinearity through a large sample size, and determine the potential influence of nonlinearity and its possible mechanisms.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    In total, 906 trough concentrations from 176 adult patients (150 men\/26 women; average age: 50.68 \u00b1 9.71 years, average weight: 64.54 \u00b1 11.85\u00a0kg after first liver transplantation) were included in this study. Population pharmacokinetic analysis was performed using NONMEM\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . Two modeling strategies, theory-based linear compartmental and nonlinear Michaelis\u2013Menten (MM) models, were evaluated and compared. Potential covariates were screened using a stepwise approach. Bootstrap, prediction-, and simulation-based diagnostics (prediction-corrected visual predictive checks) were performed to determine model stability and predictive performance. Finally, Monte Carlo simulations based on the superior model were conducted to design dosing regimens.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Postoperative days (POD), Aspartate aminotransferase (AST), daily tacrolimus dose, triazole antifungal agent (TAF) co-therapy, and recipient\n                    <jats:italic>CYP3A5*3<\/jats:italic>\n                    genotype constituted the main factors in the theory-based compartmental final model, whereas POD, Total serum bilirubin (TBIL), Haematocrit (HCT), TAF co-therapy, and recipient\n                    <jats:italic>CYP3A5*3<\/jats:italic>\n                    genotype were important in the nonlinear MM model. The theory-based final model exhibited 234\u00a0L\u00a0h\n                    <jats:sup>\u22121<\/jats:sup>\n                    apparent plasma clearance and 11,000\u00a0L plasma distribution volume. The maximum dose rate (\n                    <jats:italic>V<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>max<\/jats:italic>\n                    <\/jats:sub>\n                    ) of the nonlinear MM model was 6.62 mg\u00a0day\n                    <jats:sup>\u22121<\/jats:sup>\n                    ; the average concentration at steady state at half-\n                    <jats:italic>V<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>max<\/jats:italic>\n                    <\/jats:sub>\n                    (\n                    <jats:italic>K<\/jats:italic>\n                    <jats:sub>\n                      <jats:italic>m<\/jats:italic>\n                    <\/jats:sub>\n                    ) was 6.46\u00a0ng\u00a0ml\n                    <jats:sup>\u22121<\/jats:sup>\n                    . The nonlinear MM final model was superior to the theory-based final model and used to propose dosing regimens based on simulations.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our findings demonstrate that saturated tacrolimus concentration-dependent binding to erythrocytes and the influence of daily tacrolimus dose on metabolism may partly contribute to nonlinearity. Further investigation is needed is need to explore the causes of nonlinear pharmacokinetic of tacrolimus. The nonlinear MM model can provide reliable support for tacrolimus dosing optimization and adjustment in adult patients undergoing liver transplantation.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.1031969","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:30:46Z","timestamp":1667953846000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: A comparison of Michaelis-Menten and theory-based pharmacokinetic models"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao-Jun","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Feng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-Bao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Huan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Fei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","article-title":"Inherent correlation between dose and clearance in therapeutic drug monitoring settings: Possible misinterpretation in population pharmacokinetic analyses","volume":"32","author":"Ahn","year":"2005","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00002018-199818020-00001","article-title":"Systemic antifungal agents. Drug interactions of clinical significance","volume":"18","author":"Albengres","year":"1998","journal-title":"Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e935938","DOI":"10.12659\/AOT.935938","article-title":"Tacrolimus-induced neurotoxicity in early post-liver transplant Saudi patients: Incidence and risk factors","volume":"27","author":"Alissa","year":"2022","journal-title":"Ann. Transpl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","article-title":"A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: A population approach","volume":"56","author":"Andreu","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02895.x","article-title":"Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients","volume":"64","author":"Antignac","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/TP.0b013e31826c3985","article-title":"NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation","volume":"94","author":"Barraclough","year":"2012","journal-title":"Transplantation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1177\/00912700122010519","article-title":"Comparative tacrolimus pharmacokinetics: Normal versus mildly hepatically impaired subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/s0149-2918(00)87237-9","article-title":"Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg","volume":"21","author":"Bekersky","year":"1999","journal-title":"Clin. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity [J]","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif. Organs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","article-title":"Population pharmacokinetic modelling and bayesian estimation of tacrolimus exposure: Is this clinically useful for dosage prediction yet? [J]","volume":"55","author":"Brooks","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"105237","DOI":"10.1016\/j.ejps.2020.105237","article-title":"Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients","volume":"2020","author":"Cai","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","article-title":"Population pharmacokinetics of tacrolimus in transplant recipients: What did we learn about sources of interindividual variabilities? [J]","volume":"59","author":"Campagne","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B13","first-page":"610","article-title":"Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion","volume":"25","author":"Chow","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"B14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus","volume":"41","author":"Christians","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/pharmaceutics14020379","article-title":"The role of intra-patient variability of tacrolimus drug concentrations in solid organ transplantation: A focus on liver, heart, lung and pancreas","volume":"14","author":"Coste","year":"2022","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/FTD.0b013e3181aa36cd","article-title":"New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: Possible consequences for therapeutic drug monitoring in solid organ transplantation","volume":"31","author":"De Jonge","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"B17","doi-asserted-by":"publisher","first-page":"146007","DOI":"10.1016\/j.gene.2021.146007","article-title":"CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation","volume":"809","author":"Dong","year":"2022","journal-title":"Gene"},{"key":"B18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/TP.0b013e318278d367","article-title":"Interpreting tacrolimus concentrations during pregnancy and postpartum","volume":"95","author":"Hebert","year":"2013","journal-title":"Transplantation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/00007890-199311000-00008","article-title":"Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C","volume":"56","author":"Horina","year":"1993","journal-title":"Transplantation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"105199","DOI":"10.1016\/j.ejps.2019.105199","article-title":"Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear michaelis-menten pharmacokinetic model","volume":"143","author":"Huang","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/FTD.0000000000000182","article-title":"Effect of genetic polymorphism of CYP3A5 and CYP2C19 and concomitant use of voriconazole on blood tacrolimus concentration in patients receiving hematopoietic stem cell transplantation","volume":"37","author":"Iwamoto","year":"2015","journal-title":"Ther. Drug Monit."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.2147\/TCRM.S184376","article-title":"CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation","volume":"14","author":"Ji","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"B23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00003088-200241050-00005","article-title":"Pharmacokinetic interaction between tacrolimus and diltiazem: Dose-response relationship in kidney and liver transplant recipients","volume":"41","author":"Jones","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.2147\/IJN.S102991","article-title":"Enhanced dissolution and oral absorption of tacrolimus by supersaturable self-emulsifying drug delivery system","volume":"11","author":"Lee","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1592\/phco.26.8.1069","article-title":"Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients","volume":"26","author":"Lee","year":"2006","journal-title":"Pharmacotherapy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","article-title":"Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients","volume":"32","author":"Li","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/tpj.2010.42","article-title":"Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: From retrospective to prospective","volume":"11","author":"Li","year":"2011","journal-title":"Pharmacogenomics J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s10620-012-2412-0","article-title":"Non-adherence and graft failure in adult liver transplant recipients","volume":"58","author":"Lieber","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","article-title":"The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients","volume":"70","author":"Lunde","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/jcpt.12834","article-title":"Influence of azole antifungal drugs on blood tacrolimus levels after switching from intravenous tacrolimus to once-daily modified release tacrolimus in patients receiving allogeneic hematopoietic stem cell transplantation","volume":"44","author":"Mimura","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"B33","first-page":"633","article-title":"The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects","volume":"27","author":"Moller","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"B34","doi-asserted-by":"publisher","first-page":"S270","DOI":"10.1007\/s001470050476","article-title":"Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients","volume":"11","author":"Pou","year":"1998","journal-title":"Transpl. Int."},{"key":"B35","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.phymed.2012.11.008","article-title":"Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus","volume":"20","author":"Qin","year":"2013","journal-title":"Phytomedicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2165\/00003088-200645010-00004","article-title":"Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients","volume":"45","author":"Sam","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1006\/jsre.2002.6359","article-title":"Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus","volume":"103","author":"Shimomura","year":"2002","journal-title":"J. Surg. Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/jlts.2003.50023","article-title":"Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation","volume":"9","author":"Staatz","year":"2003","journal-title":"Liver Transpl."},{"key":"B40","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bcp.12361","article-title":"Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling","volume":"78","author":"Storset","year":"","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"Storset","year":"","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B42","first-page":"72","article-title":"Evidence-based guidelines on diagnosis and treatment of childhood common renal diseases (III): Guideline on diagnosis and treatment of steroid-resistant nephrotic syndrome","volume":"48","year":"2010","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B43","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/jps.10041","article-title":"Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats","volume":"91","author":"Tamura","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/bdd.2311","article-title":"Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients","volume":"43","author":"Teng","year":"2022","journal-title":"Biopharm. Drug Dispos."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1007\/s11095-006-9020-7","article-title":"In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect","volume":"23","author":"Tubic","year":"2006","journal-title":"Pharm. Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/TP.0b013e3182629e13","article-title":"Effect of mild diarrhea on tacrolimus exposure","volume":"94","author":"Van Boekel","year":"2012","journal-title":"Transplantation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s40262-016-0414-3","article-title":"A semi-physiological population model to quantify the effect of hematocrit on Everolimus pharmacokinetics and pharmacodynamics in cancer patients","volume":"55","author":"Van Erp","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","article-title":"Clinical determinants of calcineurin inhibitor disposition: A mechanistic review","volume":"48","author":"Vanhove","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s13312-021-2262-y","article-title":"Consensus guidelines on management of steroid-resistant nephrotic syndrome","volume":"58","author":"Vasudevan","year":"2021","journal-title":"Indian Pediatr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"SP307","DOI":"10.2131\/jts.34.sp307","article-title":"Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children","volume":"34","author":"Yokoi","year":"2009","journal-title":"J. Toxicol. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/liv.13597","article-title":"Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation","volume":"38","author":"Zhang","year":"2018","journal-title":"Liver Int."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e18150","DOI":"10.1097\/MD.0000000000018150","article-title":"Clinical observation on the effect of Wuzhi soft capsule on FK506 concentration in membranous nephropathy patients","volume":"98","author":"Zhang","year":"2019","journal-title":"Med. Baltim."},{"key":"B54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","article-title":"External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients","volume":"81","author":"Zhao","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3109\/00498254.2015.1021733","article-title":"Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T\/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients","volume":"45","author":"Zhu","year":"2015","journal-title":"Xenobiotica."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1031969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:30:53Z","timestamp":1667953853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1031969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":55,"alternative-id":["10.3389\/fphar.2022.1031969"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1031969","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"article-number":"1031969"}}